NC
ALXN

Nicholas Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Nicholas Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-48,325
Closed -$4.73M – 227
2019
Q3 		$4.73M Sell
48,325
-40
-0.1% -$4.51K 0.11% 189
2019
Q2 		$6.33M Sell
48,365
-225
-0.5% -$29K 0.14% 158
2019
Q1 		$6.57M Buy
48,590
+85
+0.2% +$10.6K 0.16% 150
2018
Q4 		$4.72M Hold
48,505
– – 0.12% 179
2018
Q3 		$6.74M Buy
48,505
+105
+0.2% +$13.2K 0.15% 155
2018
Q2 		$6.01M Buy
48,400
+5,630
+13% +$658K 0.14% 159
2018
Q1 		$4.77M Buy
+42,770
New +$5.11M 0.11% 182
2017
Q2 		– Sell
-50,265
Closed -$6.09M – 223
2017
Q1 		$6.09M Buy
50,265
+40
+0.1% +$5.16K 0.14% 131
2016
Q4 		$6.14M Buy
50,225
+5,020
+11% +$614K 0.14% 130
2016
Q3 		$5.54M Buy
45,205
+9,990
+28% +$1.29M 0.12% 131
2016
Q2 		$4.11M Hold
35,215
– – 0.08% 153
2016
Q1 		$4.9M Buy
35,215
+2,685
+8% +$394K 0.1% 127
2015
Q4 		$6.21M Hold
32,530
– – 0.12% 116
2015
Q3 		$5.09M Hold
32,530
– – 0.1% 120
2015
Q2 		$5.88M Buy
32,530
+17,520
+117% +$3.02M 0.1% 124
2015
Q1 		$2.6M Buy
+15,010
New +$2.72M 0.05% 199

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nicholas Company's ALXN Position: Q4 2019 in Review

Nicholas Company sold out of Alexion Pharmaceuticals (ALXN) in Q4 2019, closing a stake of 48,325 shares — an estimated $4.73M sold.

Nicholas Company first reported a position in ALXN in Q1 2015 and held it in 16 quarters. The position peaked at $6.74M in Q3 2018. 669 funds tracked by Wall St. Rank hold ALXN as of Q4 2019.

  • Nicholas Company reported no remaining Alexion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Nicholas Company sold 48,325 Alexion Pharmaceuticals shares in Q4 2019, an estimated $4.73M.
  • Nicholas Company first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 16 quarters.
  • Nicholas Company's Alexion Pharmaceuticals position peaked at $6.74M in Q3 2018.
  • 669 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2019.

Based on Nicholas Company's 13F filing for Q4 2019, filed 13 Feb 2020.